Clincosm LogoSign in Get a demo

psa progression

Showing 1 - 14 of 14
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer, PSA Progression Trial in Portland (drug, other,

Active, not recruiting
  • Castration-Resistant Prostate Carcinoma
  • +4 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Sep 26, 2022

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma Trial in Detroit,

Active, not recruiting
  • Castration Levels of Testosterone
  • +4 more
  • Detroit, Michigan
  • +1 more
Aug 30, 2022

Prostate Adenocarcinoma, PSA Progression, Recurrent Prostate Carcinoma Trial in Palo Alto (Gallium Ga 68 DOTA-NeoBOMB1, Gallium

Suspended
  • Prostate Adenocarcinoma
  • +2 more
  • Gallium Ga 68 DOTA-NeoBOMB1
  • Gallium Ga 68 PSMA-R2
  • Palo Alto, California
    Stanford Cancer Institute Palo Alto
May 3, 2022

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory

Active, not recruiting
Has Results
  • Castration Levels of Testosterone
  • +9 more
  • Recombinant EphB4-HSA Fusion Protein
  • Los Angeles, California
  • +2 more
Apr 4, 2022

PSA Progression, Stage III Prostate Adenocarcinoma, Stage IV Prostate Adenocarcinoma Trial in Canada, United States (drug,

Active, not recruiting
  • PSA Progression
  • +2 more
  • Gilbert, Arizona
  • +362 more
Mar 9, 2022

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma Trial in Houston,

Active, not recruiting
  • Castration Levels of Testosterone
  • +4 more
  • Abiraterone Acetate
  • +6 more
  • Houston, Texas
  • +2 more
Feb 11, 2022

Prostate Adenocarcinoma, PSA Level Greater Than 0.2, PSA Level Greater Than or Equal to Two Trial in Palo Alto (procedure,

No longer available
  • Prostate Adenocarcinoma
  • +4 more
  • Computed Tomography
  • +3 more
  • Palo Alto, California
    Stanford Cancer Institute Palo Alto
Jan 6, 2022

PSA Level Greater Than 0.03, PSA Progression, Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7

Active, not recruiting
  • PSA Level Greater Than 0.03
  • +4 more
  • Antiandrogen Therapy
  • +2 more
  • Los Angeles, California
  • +1 more
Oct 14, 2021

Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma Trial in Los Angeles

Completed
  • Biochemically Recurrent Prostate Carcinoma
  • +8 more
  • Computed Tomography
  • +3 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Sep 29, 2021

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, PSA Progression Trial in San Francisco (Apalutamide,

Recruiting
  • Castration Levels of Testosterone
  • +3 more
  • San Francisco, California
    University of California, San Francisco
Aug 26, 2021

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue

Withdrawn
  • Castration Levels of Testosterone
  • +8 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Mar 31, 2021

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone Trial in

Recruiting
  • Castration Levels of Testosterone
  • +4 more
  • HER2Bi-Armed Activated T Cells
  • +2 more
  • Detroit, Michigan
    Wayne State University/Karmanos Cancer Institute
Feb 26, 2021

Drug Resistance in Metastatic Castration-Resistant Prostate

Completed
  • Castration Levels of Testosterone
  • +5 more
  • Cytology Specimen Collection Procedure
  • +2 more
  • Los Angeles, California
  • +2 more
Sep 24, 2020

Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma in the Soft Tissue Trial in

Terminated
Has Results
  • Castration Levels of Testosterone
  • +5 more
  • San Francisco, California
    University of California, San Francisco
May 29, 2018